GSK’s Nu­cala wins COPD ap­proval, stok­ing ri­val­ry with Dupix­ent 

GSK’s block­buster res­pi­ra­to­ry drug Nu­cala was ap­proved Thurs­day for cer­tain pa­tients with chron­ic ob­struc­tive pul­monary dis­ease, set­ting up a show­down with Sanofi and Re­gen­eron’s Dupix­ent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER